Extracting the mutation sites of Hepatitis B virus (HBV) from the provided pdf file `benchmark/dataset/ViMIC/12985_2021_Article_1493.pdf`.

Saving the results into a json file `/root/autodl-tmp/biomni_v20260208_pred_results/doubao-seed-1-8/vimic_extract.json`.

Result format reference:
[
  "G130E",
  "L109R"
]

All intermediate results should be saved in `/root/autodl-tmp/biomni_v20260208_tmp/doubao-seed-1-8/vimic_extract` directory.

<execute>
import pdfplumber
import os

# Define paths
pdf_path = "benchmark/dataset/ViMIC/12985_2021_Article_1493.pdf"
tmp_dir = "/root/autodl-tmp/biomni_v20260208_tmp/doubao-seed-1-8/vimic_extract"
output_json = "/root/autodl-tmp/biomni_v20260208_pred_results/doubao-seed-1-8/vimic_extract.json"

# Create tmp directory if it doesn't exist
os.makedirs(tmp_dir, exist_ok=True)

# Check if PDF exists
if os.path.exists(pdf_path):
    print(f"Found PDF file at {pdf_path}")
else:
    print(f"PDF file not found at {pdf_path}")

# Read the first few pages to inspect content
with pdfplumber.open(pdf_path) as pdf:
    # Print number of pages
    print(f"Total pages: {len(pdf.pages)}")
    
    # Extract text from first 5 pages and save to tmp for inspection
    with open(os.path.join(tmp_dir, "first_5_pages.txt"), "w", encoding="utf-8") as f:
        for i in range(min(5, len(pdf.pages))):
            page = pdf.pages[i]
            text = page.extract_text()
            f.write(f"--- Page {i+1} ---\n")
            f.write(text)
            f.write("\n\n")
    
    print("Extracted first 5 pages to tmp directory for inspection")
</execute>
<observation>Found PDF file at benchmark/dataset/ViMIC/12985_2021_Article_1493.pdf
Total pages: 10
Extracted first 5 pages to tmp directory for inspection
</observation>
<execute>
#!BASH
cat /root/autodl-tmp/biomni_v20260208_tmp/doubao-seed-1-8/vimic_extract/first_5_pages.txt
</execute>
<observation>The output is too long to be added to context. Here are the first 10K characters...
--- Page 1 ---
Opaleye et al. Virol J (2021) 18:20
https://doi.org/10.1186/s12985-021-01493-4
RESEARCH Open Access
Prevalence and characteristics of hepatitis
B and D virus infections among HIV-positive
individuals in Southwestern Nigeria
Oluyinka Oladele Opaleye1†, Olusola Anuoluwapo Akanbi1,2†, Folakemi Abiodun Osundare1,2, Bo Wang2,
Olufisayo Adesina2,3, Adeolu Sunday Oluremi1, Sola Thomas Sunday1, Abiodun Akeem Akindele1,
Patrycja Klink2 and C. Thomas Bock2,4*
Abstract
Background: Coinfections of HIV-positive individuals with Hepatitis B and D virus (HBV and HDV) are common and
can be associated with rapid liver damage. Several antiretroviral drugs for HIV exhibit anti-HBV effect; however, the
selection of HBV drug resistance mutations (DRMs) in individuals under HIV antiretroviral therapy (ART) has been
reported but rarely in Nigeria. In this study the HBV/HDV prevalence and HBV DRMs in HIV-positive individuals in
Southwestern Nigeria were assessed.
Methods: Plasma samples collected from 310 HIV-positive individuals including 295 ART-experienced and 15 ART-
naïve persons attending the HIV clinic in three south-western states of Nigeria between June 2017 and August 2017
were analysed by ELISA for HBsAg and anti-HDV. The presence of HDV RNA and HBV DNA was analysed by (RT)-PCR
followed by sequencing and phylogenetic analyses for genotyping. The HBV reverse transcription (RT) region was
amplified and sequenced for the analysis of drug resistance mutations.
Results: Overall, 16.1% (n 50/310) of the HIV-positive individuals were positive for HBsAg, most of which were ART-
=
experienced (94.0%; n 47/50). From the 50 HBsAg-positive samples, 72.0% (n 36/50) were positive for HBV DNA
= =
and 16.0% (n 8/50) had detectable HDV RNA while 5.6% (n 2/36) of the HBV-DNA positive samples had anti-HDV
= =
total antibodies. Sequences were available for 31/36 of the HBV DNA-positive and 3/8 HDV RNA-positive samples.
HBV DNA-positive samples were characterised as HBV genotype E infections exclusively, while HDV genotype 1 was
detected in the HDV RNA-positive samples. HBV DRMs V173L, L180M, S202I and M204V/I, which are associated with
lamivudine resistance, were detected in 32.2% (n 10/31) of the HBV DNA-positive samples. Most of these mutations
=
(90.0%; n 9/10) were present in the ART-experienced cohort.
=
Conclusions: This study indicates that HBV/HDV coinfections are common in HIV-positive individuals under ART in
Nigeria. Furthermore, a high proportion of HBV DRMs which potentially compromise future treatment options were
detected, underscoring the need for HBV screening prior to starting ART. Further studies should be performed to
monitor a possible increase in the spread of HDV among populations at risk of HIV and HBV infections.
*Correspondence: bockc@rki.de
†Oluyinka Oladele Opaleye and Olusola Anuoluwapo Akanbi contributed
equally to the work and thus shared first authorship
2 Division of Viral Gastroenteritis and Hepatitis Pathogens
and Enteroviruses, Department of Infectious Diseases, Robert Koch
Institute, Berlin, Germany
Full list of author information is available at the end of the article
© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this
licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecom-
mons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

--- Page 2 ---
Opaleye et al. Virol J (2021) 18:20 Page 2 of 10
Keywords: HBV, HDV, HIV, Co-infection, Drug resistance, ART , Nigeria
Background monitoring and selection of ART regimen. This study
Due to shared routes of transmission, co-infection of HIV was carried out to investigate the prevalence and geno-
with hepatitis viruses is common worldwide and it is esti- type distribution of HBV and HDV in HIV-positive
mated that 5–20% of the approximately 37 million people individuals in Southwestern Nigeria. Furthermore, the
living with HIV are co-infected with HBV [1]. In Africa presence of HBV DRMs in ART-experienced and naïve
(Nigeria inclusive), HBV is hyper-endemic and HBV/HIV HIV-infected individuals was analysed.
co-infections are highly prevalent [2]. Compared to HBV
Methods
or HIV mono-infected individuals, co-infected individu-
als have a higher risk of impaired immunological recov- Study population
ery and hepatotoxicity during antiretroviral treatment Plasma samples were randomly collected from 310 HIV-
(ART) and a faster rate of progression to cirrhosis and positive individuals including 295 ART-experienced
hepatocellular carcinoma [3, 4]. and 15 ART-naive HIV-positive persons. The samples
The prevalence of HDV is about 5% among HBV carri- were collected from the HIV clinics of Adeoyo hospital,
ers however, rates between 3 and 30% have been reported Ibadan, Oyo state (82 samples) and LAUTECH teach-
in West Africa [5–7]. HDV co-infection increases the risk ing hospital, Osogbo, Osun state (100 samples) and Offa,
for hepatitis flares and chronic hepatic complications Kwara state (128 samples) both located in the southwest-
especially in individuals with HBV/HIV co-infection [8]. ern region of Nigeria. Samples were collected between
However, the impact of HDV infection on HIV/HBV co- June and August 2017. Informed consent of each partici-
infected individuals is not well documented, especially in pant was obtained before sample collection and the study
Nigeria where HDV is not routinely diagnosed. was approved by the Ethical review board of LAUTECH
Currently, six nucleoside analogues have been Teaching Hospital, Osogbo, Nigeria. Samples were stored
approved for the treatment of chronic HBV infection, all at 80 °C until testing and all laboratory analyses were
−
of which are inhibitors of the reverse transcriptase (RT) carried out at the Robert Koch Institute, Berlin, Germany.
of HBV [9] and some of them (3TC and TDF/TAF) are
also part of the first line regimen used for HIV ART [10]. HBV and HDV serology
Administration of these drugs in HIV-positive patients Qualitative detection of HBsAg was performed using the
without knowledge of their HBV status can lead to the Wantai HBsAg ELISA (Wantai Hepatitis B virus Diag-
emergence of HBV drug resistance mutations (DRMs) nostics, China). Anti-HDV antibodies were analysed
and potentially limiting the treatment options avail- using the ETI-AB-DELTAK-2 enzyme immune-assay
able for the treatment of HBV [11]. Therefore, the World (anti-HD; DiaSorin Limited, Germany) for the qualita-
Health Organisation (WHO) [12] has recommended that tive determination of total antibodies to hepatitis delta
all HIV-infected patients should be tested for the pres- antigen. All tests were performed following the manufac-
ence of HBV prior to initiation of therapy [12], but this turer’s instructions.
is rarely done in Nigeria and some parts of sub-Saharan
Africa due to high costs or partly due to neglect of the Nucleic acid extraction and PCR amplification
disease and concentration on HIV treatment [13, 14]. Total viral nucleic acids were extracted from 140 μl of
The HBV status of most HIV-infected individuals plasma using the QIAamp MinElute Virus Spin Kit (Qia-
remains unknown, and first line ART regimen for HIV gen, Hilden, Germany) using the QIACUBE automated
contains zidovudine (AZT), lamivudine (3TC) and nevi- system (Qiagen, Hilden, Germany). Nucleic acids were
rapine (NVP) in Nigeria (https ://www.who.int/hiv/pub/ eluted in 60 µl of nuclease-free elution buffer and stored
guide lines /niger ia_art.pdf). As a result of the low genetic at 80 °C until use. For HBV genotyping, the partial
−
barrier to resistance of 3TC, [15] the risk for the emer- HBV S-gene was amplified using nested PCR as previ-
gence of drug resistant HBV strains is increased. Moreo- ously described [17]. HBV DRMs were detected by the
ver, studies have shown that HBV mutations can occur amplification of a partial coding region of the HBV RT-
even in the absence of 3TC therapy in drug-naïve HBV region designated for antiviral resistance using nested
carriers, thereby contributing to the rapid development PCR followed by population-based Sanger sequencing.
of drug resistance [16]. HDV was genotyped by HDV-specific nested RT-PCR
Thus, knowledge of HBV and HDV status among using primers designed for the amplification of a highly
HIV-infected patients is important for adequate clinical conserved region of the HDV genome (LHDAg region,

--- Page 3 ---
O paleye et al. Virol J (2021) 18:20 Page 3 of 10
nucleotide 888 to 1122) and sequencing as previously Statistical analysis
described [6, 18]. All PCR products were analysed on Statistical analyses were done by Fischer’s exact tests
1.5% Agarose gels. with SPSS version 20.0.1 for Windows. A p value < 0.05
was considered to be statistically significant.
HBV quantitative polymerase chain reaction
Results
The HBV viral load was determined by quantitative
Characteristics of the study population
real-time PCR (qPCR) using the Roche Lightcycler 480
The study population included 310 HIV-positive indi-
(Roche, Mannheim, Germany) as described previously
viduals with a median age of 40 years (range 4–73 years)
using primers in t</observation>
<execute>
import pdfplumber
import os
import re

# Define paths
pdf_path = "benchmark/dataset/ViMIC/12985_2021_Article_1493.pdf"
tmp_dir = "/root/autodl-tmp/biomni_v20260208_tmp/doubao-seed-1-8/vimic_extract"
output_json = "/root/autodl-tmp/biomni_v20260208_pred_results/doubao-seed-1-8/vimic_extract.json"

# Extract all text from PDF
with pdfplumber.open(pdf_path) as pdf:
    full_text = ""
    for page in pdf.pages:
        text = page.extract_text()
        if text:
            full_text += text + "\n"

# Save full text to tmp directory
full_text_path = os.path.join(tmp_dir, "full_text.txt")
with open(full_text_path, "w", encoding="utf-8") as f:
    f.write(full_text)

print(f"Extracted full text to {full_text_path}")

# Search for mutation patterns (e.g., V173L, M204V/I)
mutation_pattern = r'[A-Z][0-9]+[A-Z](?:\/[A-Z])?'
mutations = re.findall(mutation_pattern, full_text)

# Remove duplicates and sort
unique_mutations = sorted(list(set(mutations)))

print(f"Found {len(unique_mutations)} unique mutations:")
for mut in unique_mutations:
    print(f"- {mut}")

# Save mutations to JSON file
import json
with open(output_json, "w", encoding="utf-8") as f:
    json.dump(unique_mutations, f, indent=2)

print(f"Saved mutations to {output_json}")
</execute>
<observation>Extracted full text to /root/autodl-tmp/biomni_v20260208_tmp/doubao-seed-1-8/vimic_extract/full_text.txt
Found 6 unique mutations:
- L180M
- M204I
- M204V
- M204V/I
- S202I
- V173L
Saved mutations to /root/autodl-tmp/biomni_v20260208_pred_results/doubao-seed-1-8/vimic_extract.json
</observation>
<execute>
import json
import os

# Paths
output_json = "/root/autodl-tmp/biomni_v20260208_pred_results/doubao-seed-1-8/vimic_extract.json"
tmp_dir = "/root/autodl-tmp/biomni_v20260208_tmp/doubao-seed-1-8/vimic_extract"

# Read the current mutations
with open(output_json, "r", encoding="utf-8") as f:
    mutations = json.load(f)

# Process mutations to split combined ones (like M204V/I)
processed_mutations = []
for mut in mutations:
    if "/" in mut:
        # Split into individual mutations
        parts = mut.split("/")
        # Get the common prefix (e.g., M204)
        prefix = re.match(r'([A-Z][0-9]+)', parts[0]).group(1)
        for part in parts:
            # Get the amino acid (last character)
            aa = part[-1]
            processed_mutations.append(f"{prefix}{aa}")
    else:
        processed_mutations.append(mut)

# Remove duplicates and sort
unique_processed = sorted(list(set(processed_mutations)))

print("Processed mutations (split combined entries):")
for mut in unique_processed:
    print(f"- {mut}")

# Save the processed mutations to JSON
with open(output_json, "w", encoding="utf-8") as f:
    json.dump(unique_processed, f, indent=2)

print(f"Updated mutations saved to {output_json}")

# Save processed mutations to tmp directory
processed_path = os.path.join(tmp_dir, "processed_mutations.txt")
with open(processed_path, "w", encoding="utf-8") as f:
    for mut in unique_processed:
        f.write(f"{mut}\n")

print(f"Processed mutations saved to {processed_path}")
</execute>
<observation>NameError("name 're' is not defined")</observation>
<execute>
import json
import os
import re

# Paths
output_json = "/root/autodl-tmp/biomni_v20260208_pred_results/doubao-seed-1-8/vimic_extract.json"
tmp_dir = "/root/autodl-tmp/biomni_v20260208_tmp/doubao-seed-1-8/vimic_extract"

# Read the current mutations
with open(output_json, "r", encoding="utf-8") as f:
    mutations = json.load(f)

# Process mutations to split combined ones (like M204V/I)
processed_mutations = []
for mut in mutations:
    if "/" in mut:
        # Split into individual mutations
        parts = mut.split("/")
        # Get the common prefix (e.g., M204)
        prefix = re.match(r'([A-Z][0-9]+)', parts[0]).group(1)
        for part in parts:
            # Get the amino acid (last character)
            aa = part[-1]
            processed_mutations.append(f"{prefix}{aa}")
    else:
        processed_mutations.append(mut)

# Remove duplicates and sort
unique_processed = sorted(list(set(processed_mutations)))

print("Processed mutations (split combined entries):")
for mut in unique_processed:
    print(f"- {mut}")

# Save the processed mutations to JSON
with open(output_json, "w", encoding="utf-8") as f:
    json.dump(unique_processed, f, indent=2)

print(f"Updated mutations saved to {output_json}")

# Save processed mutations to tmp directory
processed_path = os.path.join(tmp_dir, "processed_mutations.txt")
with open(processed_path, "w", encoding="utf-8") as f:
    for mut in unique_processed:
        f.write(f"{mut}\n")

print(f"Processed mutations saved to {processed_path}")
</execute>
<observation>Processed mutations (split combined entries):
- L180M
- M204I
- M204V
- S202I
- V173L
Updated mutations saved to /root/autodl-tmp/biomni_v20260208_pred_results/doubao-seed-1-8/vimic_extract.json
Processed mutations saved to /root/autodl-tmp/biomni_v20260208_tmp/doubao-seed-1-8/vimic_extract/processed_mutations.txt
</observation>
<execute>
import json

output_json = "/root/autodl-tmp/biomni_v20260208_pred_results/doubao-seed-1-8/vimic_extract.json"

# Read and print the final JSON content
with open(output_json, "r", encoding="utf-8") as f:
    final_result = json.load(f)

print("Final result in JSON format:")
print(json.dumps(final_result, indent=2))
</execute>
<observation>Final result in JSON format:
[
  "L180M",
  "M204I",
  "M204V",
  "S202I",
  "V173L"
]
</observation>
<solution>[
  "L180M",
  "M204I",
  "M204V",
  "S202I",
  "V173L"
]</solution>